MacroGenics to Participate in Upcoming Investor Conference

Rhea-AI Summary

MacroGenics (NASDAQ: MGNX), a biopharmaceutical company specializing in antibody-based cancer therapeutics, has announced its participation in the upcoming Citizens Life Sciences Conference in New York. The company's management team will engage in a fireside chat on May 8, 2025, at 10:30am ET, along with one-on-one meetings.

A webcast of the presentation will be available in the Investor Relations section of MacroGenics' website and will remain accessible for 30 days after the event.

News Market Reaction

+4.17%

1 alert

+4.17% News Effect

On the day this news was published, MGNX gained 4.17%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

ROCKVILLE, MD, May 01, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that members of the Company's management team will participate in the following investor conference this month:

• The Citizens Life Sciences Conference (New York). Members of MacroGenics’ management team will participate in a fireside chat on Thursday, May 8, 2025, at 10:30am ET. Management will also participate in one-on-one meetings.
  
  

A webcast of the above presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain an archived replay of the webcast on its website for 30 days.

About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics, the MacroGenics logo and DART are trademarks or registered trademarks of
MacroGenics, Inc.

Contacts:
Jim Karrels, Senior Vice President, CFO
1-301-251-5172
info@macrogenics.com

Argot Partners
1-212-600-1902
macrogenics@argotpartners.com

FAQ

When is MacroGenics (MGNX) presenting at the Citizens Life Sciences Conference 2025?

MacroGenics will participate in a fireside chat at the Citizens Life Sciences Conference on Thursday, May 8, 2025, at 10:30am ET in New York.

Where can I watch MacroGenics' (MGNX) presentation at the Citizens Life Sciences Conference?

The presentation webcast will be available under 'Events & Presentations' in the Investor Relations section of MacroGenics' website at ir.macrogenics.com/events.cfm, with a 30-day replay period.

What type of meetings will MacroGenics (MGNX) management participate in at the Citizens Life Sciences Conference?

MacroGenics management will participate in a fireside chat presentation and one-on-one meetings during the conference.

What is MacroGenics' (MGNX) main business focus?

MacroGenics is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for cancer treatment.